Form 4: Replimune Group CEO Acquires Shares and Stock Options

CEO of Replimune Group, Sushil Patel, reports acquisition of shares and stock options in the company.

Summary

• On April 1, 2024, Sushil Patel, the CEO of Replimune Group, acquired 83,335 shares of common stock upon settlement of restricted stock units (RSUs) at a price of $0.
• Patel also acquired an option to purchase 250,000 shares of common stock at an exercise price of $7.73, expiring on April 1, 2034.
• 25% of the shares underlying the stock option will vest on April 1, 2025, with the remainder vesting in 36 approximately equal monthly installments thereafter.
• 25% of the RSUs will vest on May 15, 2025, and the remainder will vest in three approximately equal annual installments thereafter until May 15, 2028, subject to continuous service.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard regulatory filing detailing executive compensation. The acquisition of shares and options could be seen as a positive signal, but it's not definitively bullish.

Positives

• The CEO's acquisition of shares and stock options could be interpreted as a sign of confidence in the company's future prospects.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track management's alignment with shareholder interests.

Comparison to Industry Standards

• Executive compensation packages often include stock options and RSUs to incentivize performance and align management's interests with those of shareholders.
• Vesting schedules are typical, designed to retain executives and reward long-term value creation.
• The specific terms of the options and RSUs (exercise price, vesting schedule) would need to be compared to those of peer companies to assess their competitiveness.

Stakeholder Impact

• Shareholders may view the CEO's stock acquisitions as a positive sign of confidence in the company's future.

Key Dates